Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

11 August 2017 : Original article  

Prolonged Administration of Twice-Daily Bolus Intravenous Tacrolimus in the Early Phase After Lung Transplantation

Yutaka Hirano1ADEF, Seiichiro Sugimoto1ABCDEFG*, Toshifumi Mano1BCD, Takeshi Kurosaki2BCD, Kentaroh Miyoshi1ABC, Shinji Otani2ABC, Masaomi Yamane1ABC, Motomu Kobayashi3ABC, Shinichiro Miyoshi1ABC, Takahiro Oto2ABCDEF

DOI: 10.12659/AOT.904225

Ann Transplant 2017; 22:484-492

Abstract

BACKGROUND: Although administration of tacrolimus, whether by the enteric, sublingual, or continuous intravenous routes, has some limitations, twice-daily bolus intravenous tacrolimus administration has been shown to be beneficial in optimizing efficacy and safety after lung transplantation. However, at present, the duration of bolus intravenous tacrolimus administration is limited, and the effects of prolonged bolus intravenous tacrolimus administration remain unknown. Our study was aimed at assessing the safety and efficacy of prolonged twice-daily bolus intravenous tacrolimus administration in the early phase after lung transplantation.

MATERIAL AND METHODS: We retrospectively investigated the data of 62 recipients of lung transplantation who had received twice-daily bolus intravenous administration of tacrolimus, followed by oral tacrolimus, after lung transplantation at our institution between January 2011 and October 2015.

RESULTS: The median duration of bolus intravenous tacrolimus administration was 19 days (4–72 days). The target trough level was achieved in 89% of the patients by day 3. Acute kidney injury occurred in 27% of the patients during bolus intravenous tacrolimus. Two patients (3%) had neurotoxicity, necessitating discontinuation of tacrolimus. Suspected acute rejection requiring steroid pulse therapy occurred in 21% of patients during the follow-up period. Eight patients (13%) developed chronic lung allograft dysfunction during the follow-up period. The 1-year and 5-year survival rates after lung transplantation were 95% and 76%, respectively.

CONCLUSIONS: These results suggest that prolonged bolus intravenous tacrolimus administration in the early phase after lung transplantation is a safe and effective alternative to enteric, sublingual, or continuous intravenous administration.

Keywords: Administration, Intravenous, Graft Rejection, Immunosuppression, Lung Transplantation, Tacrolimus

0 Comments

In Press

04 Aug 2022 : Original article  

Long-Term Patency of All-in-One Sleeve Patch Graft Venoplasty in 16 Patients Who Underwent Living Donor Liv...

Ann Transplant In Press; DOI: 10.12659/AOT.936888  

22 Jul 2022 : Original article  

Diagnostic Role of Tumor Markers for Hepatocellular Carcinoma in Liver Transplantation Candidates: An Analy...

Ann Transplant In Press; DOI: 10.12659/AOT.936937  

22 Jul 2022 : Original article  

Development of a Novel Model for Predicting Postoperative Short-Term Outcome in Patients with Hepatitis B-R...

Ann Transplant In Press; DOI: 10.12659/AOT.936732  

22 Jul 2022 : Original article  

Leucine-Rich Alpha-2-Glycoprotein (LRG-1) as a Potential Kidney Injury Marker in Kidney Transplant Recipients

Ann Transplant In Press; DOI: 10.12659/AOT.936751  

Most Viewed Current Articles

26 Jan 2022 : Review article  

Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive Models

DOI :10.12659/AOT.934924

Ann Transplant 2022; 27:e934924

29 Dec 2021 : Original article  

Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...

DOI :10.12659/AOT.933588

Ann Transplant 2021; 26:e933588

24 Jul 2020 : Review article  

Kidney Transplantation in the Times of COVID-19 – A Literature Review

DOI :10.12659/AOT.925755

Ann Transplant 2020; 25:e925755

15 Mar 2022 : Case report  

Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...

DOI :10.12659/AOT.935860

Ann Transplant 2022; 27:e935860

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358